Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OPGx-RHO
- Development stage
- Preclinical
- Lead developer
- Opus Genetics
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Ophthalmic, Subretinal
01
Overview
OPGx-RHO is an AAV-based gene therapy being developed by Opus Genetics for autosomal dominant retinitis pigmentosa caused by mutations in the rhodopsin gene. It is designed as a single, mutation-independent rhodopsin replacement strategy to preserve rod photoreceptors by delivering a functional copy of RHO to retinal photoreceptors, with a first-in-human trial targeted to begin in 2026.[7][2][10] AdisInsight also lists IC 100 as an alternative designation associated with rhodopsin-mediated autosomal dominant retinitis pigmentosa.[8]
- Other names
- IC 100IC100IC-100
02
Targets
RHO (Rhodopsin)
Beyond the preview
Go deeper on OPGx-RHO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OPGx-RHO.